Advisor Group’s Axsome Therapeutics AXSM Stock Holding History

Advisor Group’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	$1K	Sell	12 -6	-33%	-$242	﹤0.01%	5095
2019 Q3	$0	Buy	+18	New	+$463	﹤0.01%	5260

Other funds holding AXSM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

VMI

VHCP Management III New York $504M AUM 683.12% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

ACM

Alethea Capital Management Mercer Island, Washington $241M AUM 112.74% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

VMI

VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return

IAM

Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Advisor Group's AXSM Position: Q4 2019 in Review

Advisor Group reduced its Axsome Therapeutics (AXSM) stake by 33% in Q4 2019, selling an estimated $242 and leaving 12 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #5095.

Advisor Group first reported a position in AXSM in Q3 2019 and has held it in 2 quarters since. 169 funds tracked by Wall St. Rank hold AXSM as of Q4 2019.

Advisor Group held 12 shares of Axsome Therapeutics worth $1K as of Q4 2019.
Advisor Group sold 6 Axsome Therapeutics shares in Q4 2019, an estimated $242.
Axsome Therapeutics made up ﹤0.01% of Advisor Group's portfolio in Q4 2019, its #5095 holding.
Advisor Group first reported a position in Axsome Therapeutics in Q3 2019 and has held it in 2 quarters since.
169 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q4 2019.

Based on Advisor Group's 13F filing for Q4 2019, filed 12 Feb 2020.